Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (November 2016)
48 slides from Elron Ventures's investor presentation, Nov 25, 2016
Slide 1: Elron - Investor Presentation, November 2016
DISCOVER. INNOVATION November 2016 ELRON - INVESTOR PRESENTATION
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the fe
Slide 3: Recent Developments
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. RECENT DEVELOPMENTS Dividend: $15 MILLION DISTRIBUTION TO SHAREHOLDERS Medical Devices:
Slide 4: 2017: Important Events
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. 2017: IMPORTANT EVENTS 4 Complete patient recruitment for FDA trial BRAINSGATE Complete
Slide 5: Discover. Elron
DISCOVER. ELRON
Slide 6: Operational Holding Company in the VC Space
OPERATIONAL HOLDING COMPANY IN THE VC SPACE WE SPECIALIZE IN MEDICAL DEVICE TECHNOLOGIES WITH SIGNIFICANT EXIT POTENTIAL + WE HAVE 50 YEARS EXPERIENCE IDENTIFYING OPPORTUNITIES, BUILDING TECHNOLOGY LEADERS, AND EXITING HOLDINGS + WE INVEST PRIMARILY IN EARLY STAGE COMPANIES+ WE RELY ON A PROVEN STRA
Slide 7: Performance in 2016
PERFORMANCE IN 2016: 114 20 59 4 269 * Including RDC * 26 LOSS (1-9/16): $17.5M INVESTMENTS *: $40M PERFORMANCE IN 2016: 20 59 4 269 * Including RDC 7 LIQUID RESOURCES *: $89M 26 SINCE 2010: AGGREGATE PROFIT OF $151M; $140M IN DIVIDENDS 114 LOSS (1-9/16): $17.5M INVESTMENTS *: $40M PERFORMANCE IN 20
Slide 8: Value Potential
VALUE POTENTIAL 1 Includes Elron’s direct holdings and its effective indirect holdings through RDC and RDSeed. Includes investments made after Sept. 30, 2016.2 Includes Elron’s balance and 50.1% of RDC’s balance.3 The above financial data are based on publicly available information and do not repres
Slide 9: Discover. BrainsGate
DISCOVER. BRAINSGATE
Slide 10: BrainsGate
BRAINSGATE ESTABLISHED: 2000FIRST INVESTMENT: 2005TOTAL INVESTMENT: $96MMAIN PARTNERS: Johnson & Johnson, Boston Scientific, Medtronic, Pitango, Cipio Partners VISION: To increase the potential number of stroke victims who receive treatment from ~7% to ~80%PRODUCT: Electrode used to electrically sti
Slide 11: ~800,000 People Suffer a Stroke Each Year in the U.S.
~800,000 PEOPLE SUFFER A STROKE EACH YEAR IN THE U.S. STROKE: INTERRUPTION OF BLOOD FLOW TO THE BRAIN When blood flow to an area of the brain is cut off blood cells begin to dieWhen brain cells die, functions controlled by that part of the brain (e.g. memory, muscle control) are lostTHE EFFECTS OF A
Slide 12: The Cost of Stroke Each Year in the U.S.: $34 Billion
THE COST OF STROKE EACH YEAR IN THE U.S.: $34 BILLION Sources: American Heart Association: Heart Disease and Stroke Statistics Report – 2010, 2015; CDC website: http://www.cdc.gov/stroke/facts.htm. 15-30% OF STROKE SURVIVORS ARE LEFT PERMANENTLY DISABLED mRS Average Lifetime Cost Per Stroke Patient
Slide 13: Why Are So Many Stroke Survivors Left Disabled?
WHY ARE SO MANY STROKE SURVIVORS LEFT DISABLED? THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH Cells in the affected area die almost immediately, and cannot be salvagedHowever, surrounding the blockage are regions
Slide 14: tPA: The Only FDA Approved Drug Treatment Since 1996
tPA: THE ONLY FDA APPROVED DRUG TREATMENT SINCE 1996 THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH CLOT-BUSTING DRUG 1 CLOT RETRIEVING DEVICES 2 ELECTRICAL STIMULATION 3 tPA: 4.5-HOUR TREATMENT WINDOWThe risk of h
Slide 15: Clot Retrievers: Add-On Treatment
THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH CLOT-BUSTING DRUG 1 CLOT RETRIEVING DEVICES 2 ELECTRICAL STIMULATION 3 CLOT RETRIEVERS: ADD-ON TREATMENTIn the past this treatment was used in an 8-hour treatment wind
Slide 16: BrainsGate: Alternate Therapy Expanding Treatment Window to 24 Hours
BRAINSGATE: ALTERNATE THERAPY THAT EXPANDS THE TREATMENT WINDOW TO 24 HOURS THE GOAL OF ALL STROKE TREATMENTS IS TO RESTORE BLOOD FLOW TO THE AFFECTED AREA AS QUICKLY AS POSSIBLE, AND PREVENT BRAIN CELL DEATH CLOT-BUSTING DRUG 1 CLOT RETRIEVING DEVICES 2 ELECTRICAL STIMULATION 3 ELECTRODE: 24-HOUR T
Slide 17: ISS: The Ischemic Stroke System
ISS: THE ISCHEMIC STROKE SYSTEM BrainsGate’s ISS is an investigational device, not approved for marketing. GuideView SPG (sphenopalatine ganglion) = supplies parasympathetic innervation to the anterior cerebral circulation and some of the posterior circulationTransmitter = emits RF waves which energ
Slide 18: Status
STATUS 18 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. BRAINSGATE IS CONDUCTING AN FDA TRIAL FOR U.S. MARKETING APPROVAL OF THE ISS,
Slide 19: Discover. Pocared
DISCOVER. POCARED
Slide 20: Pocared
POCARED ESTABLISHED: 2004FIRST INVESTMENT: 2007TOTAL INVESTMENT: $107MMAIN PARTNER: SCP Vitalife VISION: To promote antibiotic stewardship and significantly reduce lab costs by providing a method for rapid infectious diseases diagnosticsPRODUCT: Rapid and automated microbiology lab system for infect
Slide 21: Automated Lab System: The Diagnostics of Tomorrow
AUTOMATED LAB SYSTEM: THE DIAGNOSTICS OF TOMORROW In the 21st century, POCARED developed a technology for automatically identifying bacteria in body fluids, by identifying their optical “fingerprint” RAPID & AFFORDABLE TESTING THE METHODS USED IN ORGANISM IDENTIFICATION HAVEN’T CHANGED IN MORE THAN
Slide 22: Antibiotic Resistance
“Few issues in public health today are as critical and time urgent as combating the growing threat of antibiotic resistance” (Margaret A. Hamburg, M.D., Commissioner of the FDA, 2009-2015) “ ” HOW DOES ANTIBIOTIC RESISTANCE HAPPEN? The use of antibiotics is the single most important factor leading t
Slide 23: The Microbiology Lab: The Last Lab to Implement Full Automation
THE MICROBIOLOGY LAB: THE LAST LAB TO IMPLEMENT FULL AUTOMATION Sources: Bourbeau PP and Ledeboer NA (2013) Journal of Microbiology 51(6), 1658-65; Kaplan RL and Burgess TE (2010) Journal of Microbiology & Biology Education 11(2), 140-43; Novak SM and Marlowe EM (2013) Clinics in Laboratory Medicine
Slide 24: P-1000 Analyzer
The Analyzer employs algorithms that determine which wavelength to choose, and detect the organism’s “optical fingerprint” P-1000 Analyzer Sample Processor User interface The P-1000 Analyzer is investigational in the U.S., and CE-marked in the EU. The Sample Processor is exempt from regulatory appro
Slide 25: Status
STATUS 25 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. FIRST APPLICATION – Diagnosis of urinary tract infection Pocared is preparing
Slide 26: The Next Applications for Pocared's P-1000
THE NEXT APPLICATIONS FOR POCARED’S P-1000: Source: Pocared data. ANTIBIOTIC RESISTANCE(rapid AST)NO rapid solution currently availableSTATUS: clinical feasibility THROAT SWABS(streptococci)41m tests in the U.S. annuallySTATUS: clinical validation, ready for regulatory studies NASAL SWABS(MRSA/MSSA)
Slide 27: Discover. CartiHeal
DISCOVER. CARTIHEAL
Slide 28: CartiHeal
CARTIHEAL ESTABLISHED: 2009FIRST INVESTMENT: 2012TOTAL INVESTMENT: $30MMAIN PARTNERS: Johnson & Johnson, Accelmed VISION: To treat joint surface lesions, and to halt the progression of knee osteoarthritis and delay or prevent knee replacementPRODUCT: Implant for cartilage and bone repair in the join
Slide 29: Cartilage Defects Are Painful and Impair Physical Activity
29 CARTILAGE DEFECTS ARE PAINFUL AND IMPAIR PHYSICAL ACTIVITY CARTILAGE DEFECTS LEFT UNTREATED MAY PROGRESS TO OSTEOARTHRITIS No current treatment has succeeded in regenerating native cartilage Cartilage does not possess spontaneous healing potential There are no treatments that halt the progressi
Slide 30: Agili-C: Implant for Cartilage & Bone Repair in Joints
30 12 weeks post-op 6 weeks post-op 3 weeks post-op The implant has a unique structure, composed of calcium carbonate with hyaluronic acid The Agili-C is investigational in the U.S., and CE-marked in the EU. AGILI-C: IMPLANT FOR CARTILAGE & BONE REPAIR IN JOINTS
Slide 31: Status
STATUS 31 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. CARTIHEAL’S AGILI-C HAS BEEN IMPLANTED IN ~200 PATIENTS TO DATE TO TREAT TRAU
Slide 32: Discover. Notal Vision
DISCOVER. NOTAL VISION
Slide 33: Notal Vision
NOTAL VISION ESTABLISHED: 2000FIRST INVESTMENT: 2002TOTAL INVESTMENT: $55MMAIN PARTNERS: Ganot, Evergreen VISION: To save the eyesight of Age-related Macular Degeneration (AMD) patientsPRODUCT: Home-monitoring system that sends out an alert when a change for the worse is detected in the condition of
Slide 34: AMD: Age-Related Macular Degeneration
AMD: AGE-RELATED MACULAR DEGENERATION AMD destroys sharp, central vision, necessary for common tasks such as facial recognition, driving, reading, & watching television SUDDEN AND DEVASTATING DISEASE AMD has 2 stages: “dry” (non-neovascular) and “wet” (neovascular)~90% of blindness due to AMD is ass
Slide 35: ~9.1M Individuals with Dry AMD in the U.S. at Risk of Conversion
~9.1M INDIVIDUALS WITH DRY AMD IN THE U.S. ARE AT RISK OF CONVERSION TO WET AMD THE NEED FOR HOME MONITORING It is not possible to predict who will develop wet AMD, and if so, whenDry AMD patients are monitored once or twice a year, in routine check-ups at the eye doctorWet AMD can be treated, but d
Slide 36: ForeseeHome: Saving the Patient's Vision Before It's Too Late
FORESEEHOME: SAVING THE PATIENT’S VISION BEFORE IT’S TOO LATE FDA CLEAREDCE MARKEDCLINICALLY PROVENMEDICARE COVERAGEADOPTED IN THE AAOS’s CLINICAL GUIDELINES MORE THAN 2,000,000 TESTS TO DATE PROVEN PREVENTION OF VISION LOSSAREDS2: Notal Vision conducted a trial in collaboration with the NIH on 1,52
Slide 37: Status: Building a Company
STATUS 37 This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. BUILDING A COMPANY: 1 Recruited new CEO – Quinton Oswald, formerly of SARCode
Slide 38: Discover. Cloudyn
DISCOVER. CLOUDYN
Slide 39: Cloudyn
CLOUDYN ESTABLISHED: 2011FIRST INVESTMENT: 2011TOTAL INVESTMENT: $18MMAIN PARTNERS: InfoSys, Carmel Ventures, Titanium Investments VISION: To enable enterprises to fully realize their cloud potentialPRODUCT: SaaS tools for monitoring and optimizing hybrid cloud costs and usage OUR INVESTMENT:$6M OUR
Slide 40: ~80% of Enterprises Have Hybrid Cloud Environments
~80% OF ENTERPRISES HAVE HYBRID CLOUD ENVIRONMENTS 40 Source: ScienceLogic Annual Report on Hybrid IT Trends, http://www.sciencelogic.com/cloud-adoption-survey/ THE PROBLEM:62% OF HYBRID CLOUD MANAGERS HAVE LITTLE VISIBILITY | 52% DON’T HAVE A WAY TO DETERMINE WHAT THEY ARE PAYING FOR | 75% DON’T HA
Slide 41: Cloudyn Provides Unprecedented Insights
CLOUDYN PROVIDES UNPRECEDENTED INSIGHTS DERIVED FROM OPERATIONAL & FINANCIAL METRICS 41 THE SOLUTION: VISIBILITY Cloudyn’s solutions enable enterprises to gain granular, real-time visibility into consumption, cost & performance of multi-platform hybrid clouds ACCOUNTABILITY Cloudyn empowers enterpri
Slide 42: Cloudyn Raises $4M from Infosys
CLOUDYN RAISES $4M FROM INFOSYS 42
Slide 43: Discover. OpenLegacy
DISCOVER. OPENLEGACY
Slide 44: OpenLegacy
OPENLEGACY ESTABLISHED: 2013FIRST INVESTMENT: 2014TOTAL INVESTMENT: $8.5MMAIN PARTNERS: Entrepreneurs VISION: To deliver any core application as a digital servicePRODUCT: Tools that rapidly extract the services and information from legacy systems, and automatically transform them into mobile, web, &
Slide 45: Numerous Enterprises Run on IT Systems Frozen in Time
45 NUMEROUS ENTEPRISES RUN ON IT SYSTEMS THAT ARE FROZEN IN TIME LEGACY SYSTEM = AN OUTDATED COMPUTER SYSTEM, SOMETIMES DATING BACK TO THE 1970s-1980s WHY DO ENTERPRISES RELY ON OUTDATED IT SYSTEMS FOR CRITICAL APPLICATIONS? Legacy systems preserve valuable business knowledgeReplacing/upgrading IT s
Slide 46: OpenLegacy: Instant Delivery of Enterprise Core Applications as Digital Services
46 OPENLEGACY: INSTANT DELIVERY OF ENTERPRISE CORE APPLICATIONS AS DIGITAL SERVICES AT A FRACTION OF THE COST OPENLEGACY REVOLUTIONIZES LEGACY MODERNIZATION, OFFERING INDEPENDENCE FROM EXPENSIVE VENDORS, AND ELIMINATING HIGH COSTS AND HIGH RISK Reduced time to market (TTM) A fraction of the cost (TC
Slide 47: Our Cyber Companies
OUR CYBER COMPANIES 47 IRONSCALESProtecting enterprises from cyber phishing attacks27% by RDCOur investment: $1.5m SIXGILLCyber intelligence platform that analyzes the dark web22%Our investment: $2.5m SECUREDTOUCHReal time identity verification for mobile apps and mobile websites29% by RDCOur invest
Slide 48: Elron. Opportunity. Thank you.
ELRON. OPPORTUNITY Thank you.elron.com
Elron Electronic Industries — Investor Presentation (November 2016) on 6ix